Longeveron Named a Finalist Team and Will Receive a $1,000,000 Milestone 2 Award for the XPRIZE Healthspan Global Competition

• Longeveron selected as a Milestone 2 Awardee based on published clinical trial results which demonstrated laromestrocel increased 6-minute walk distance in patients with Aging-related Frailty

MIAMI, Aug. 11, 2026 — Longeveron Inc. (NASDAQ: LGVN), a clinical-stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that it has been selected from over 600 worldwide applicants to advance to the final phase of the XPRIZE Healthspan competition as a Milestone 2 Awardee team. Longeveron will receive the $1,000,000 Milestone 2 Award to be used towards the future competition clinical trial in accordance with the XPRIZE competition rules, with the opportunity to compete for the XPRIZE Grand Prize of up to $81 million.

XPRIZE Healthspan is a 7-year global competition incentivizing teams to develop and test therapeutics that restore muscle, cognition, and immune function in adults aged 50 to 90 by a minimum of 10 years, with an ambitious goal of 20 years, to extend healthy life within one year or less of treatment.

“We are extremely proud and enthusiastic to participate as a Milestone 2 Awardee of XPRIZE Healthspan, a 7-year, $101 million global competition that aims to revolutionize the way we approach human aging,” said Stephen H. Willard, Chief Executive Officer of Longeveron. “We look forward to the next chapter of the competition as we continue to develop our stem cell therapy that we believe has the potential to have a significant impact for patients and their families, and extend healthy life.”

“Our stem cell therapy laromestrocel is an allogeneic mesenchymal stem cell supported by a robust intellectual property portfolio of 52 issued patents worldwide. Its potential mechanisms of action comprising anti-inflammatory, pro-vascular, and pro-regenerative effects support its potential application across multiple important indications with high unmet medical need,” commented Dr. Joshua Hare, Co-Founder, Chief Science Officer and Executive Chairman of Longeveron. “Laromestorcel has delivered several positive initial results across 5 clinical trials in 3 indications - Alzheimer’s Disease, Aging-related Frailty, and Hypoplastic Left Heart Syndrome (HLHS), a rare pediatric and orphan-designated disease. Based on positive initial data, laromestrocel development programs have received five U.S. FDA designations: for the HLHS program - Orphan Drug designation, Fast Track designation, and Rare Pediatric Disease designation; and, for the Alzheimer’s Disease program - Regenerative Medicine Advanced Therapy (RMAT) designation and Fast Track designation. We continue to advance a “pipeline-in-a-product” strategy, with multiple indications that can be independently developed, partnered, or licensed, creating multiple potential pathways for value creation.”

XPRIZE team applications were rigorously evaluated for scientific merit and clinical readiness to identify the best, most feasible, and safe approaches to increase human healthspan. The Milestone 2 Awardees, out of more than 600 applicants across 58 countries, were selected as Finalist Awardees. The XPRIZE criteria was that the Finalist Awardees must present a single or combination therapeutic approach that demonstrates feasibility and potential to restore or preserve muscular, cognitive, and immune function lost to age-related degradation by at least 10 years, with an ambitious goal of 20 years, and deliver their therapy in 1-year or less in adults aged 50-90 years who are free of major or life-threatening disease and disability. The Top 10 Milestone 2 Award-winning teams are each receiving $1,000,000 to advance their therapeutic approach into the final phase of the competition, where teams will conduct coordinated clinical trials through 2029. The grand prize will award up to $81 million to the winning team.

About XPRIZE

XPRIZE is the recognized global leader in designing and executing large-scale competitions to solve humanity’s greatest challenges. For 30 years, our unique model has democratized crowd-sourced innovation and scientifically scalable solutions that accelerate a more equitable and abundant future. Donate, learn more, and co-architect a world of abundance with us at XPRIZE.org.

About Longeveron Inc.

Longeveron is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. The Company’s lead investigational product is laromestrocel (Lomecel-B®), an allogeneic mesenchymal stem cell (MSC) therapy product isolated from the bone marrow of young, healthy adult donors. Laromestrocel has multiple potential mechanisms of action encompassing pro-vascular, pro-regenerative, anti-inflammatory, and tissue repair and healing effects with broad potential applications across a spectrum of disease areas. Longeveron is pursuing four pipeline indications: hypoplastic left heart syndrome (HLHS), Alzheimer’s disease (AD), Pediatric Dilated Cardiomyopathy (DCM) and Aging-related Frailty. Laromestrocel development programs have received five distinct and important U.S. FDA designations: for the HLHS program - Orphan Drug designation, Fast Track designation, and Rare Pediatric Disease designation; and, for the AD program - Regenerative Medicine Advanced Therapy (RMAT) designation and Fast Track designation. For more information, visit www.longeveron.com or follow Longeveron on LinkedIn, X, and Instagram.

Investor and Media Contact

Derek Cole Investor Relations Advisory Solutions [email protected]

Photos accompanying this announcement are available at:

https://www.globenewswire.com/NewsRoom/AttachmentNg/cde71c09-a5f1-424d-837b-80f8786d82a5

https://www.globenewswire.com/NewsRoom/AttachmentNg/f106bde7-972a-4687-a91e-03e924f409fc